Heterogeneity and Progression of Chronic Obstructive Pulmonary Disease: Emphysema-Predominant and Non–Emphysema-Predominant Disease
American Journal of Epidemiology · 10.10.2023 · 192 (10) · 1647-1658
DOI: 10.1093/aje/kwad114 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift American Journal of Epidemiology, online erschienen am 09.05.2023. Verfasst von Peter J Castaldi und 11 weiteren Autor:innen. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema, Emphysema. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute, M.H.C.
Themen: COPD
Abstract (Originalsprache)
While variation in emphysema severity between patients with chronic obstructive pulmonary disease (COPD) is well-recognized, clinically applicable definitions of the emphysema-predominant disease (EPD) and non–emphysema-predominant disease (NEPD) subtypes have not been established. To study the clinical relevance of the EPD and NEPD subtypes, we tested the association of these subtypes with prospective decline in forced expiratory volume in 1 second (FEV1) and mortality among 3,427 subjects with Global Initiative for Chronic Obstructive Lung Disease (GOLD) spirometric grade 2–4 COPD at baseline in the Genetic Epidemiology of COPD (COPDGene) Study, an ongoing national multicenter study that started in 2007. NEPD was defined as airflow obstruction with less than 5% computed tomography (CT) quantitative densitometric emphysema at −950 Hounsfield units, and EPD was defined as airflow obstruction with 10% or greater CT emphysema. Mixed-effects models for FEV1 demonstrated larger average annual FEV1 loss in EPD subjects than in NEPD subjects (−10.2 mL/year; P < 0.001), and subtype-specific associations with FEV1 decline were identified. Cox proportional hazards models showed higher risk of mortality among EPD patients versus NEPD patients (hazard ratio = 1.46, 95% confidence interval: 1.34, 1.60; P < 0.001). To determine whether the NEPD/EPD dichotomy is captured by previously described COPDGene subtypes, we used logistic regression and receiver operating characteristic (ROC) curve analysis to predict NEPD/EPD membership using these previous subtype definitions. The analysis generally showed excellent discrimination, with areas under the ROC curve greater than 0.9. The NEPD and EPD COPD subtypes capture important aspects of COPD heterogeneity and are associated with different rates of disease progression and mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Förderung
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
- M.H.C
- GlaxoSmithKline and Bayer
- Boehringer-Ingelheim
- Novartis
- Bayer
- Vertex Pharmaceuticals
Zitieren
APA
Castaldi, P. J., Xu, Z., Young, K. A., Hokanson, J. E., Lynch, D. A., Humphries, S. M., Ross, J. C., Cho, M. H., Hersh, C. P., Crapo, J. D., Strand, M., & Silverman, E. K. (2023). Heterogeneity and Progression of Chronic Obstructive Pulmonary Disease: Emphysema-Predominant and Non–Emphysema-Predominant Disease. American Journal of Epidemiology, 192(10), 1647-1658. https://doi.org/10.1093/aje/kwad114
Vancouver
Castaldi PJ, Xu Z, Young KA, Hokanson JE, Lynch DA, Humphries SM, et al. Heterogeneity and Progression of Chronic Obstructive Pulmonary Disease: Emphysema-Predominant and Non–Emphysema-Predominant Disease. American Journal of Epidemiology. 2023;192(10):1647-1658. doi:10.1093/aje/kwad114
BibTeX
@article{Castaldi2023,
author = {Castaldi, Peter J and Xu, Zhonghui and Young, Kendra A and Hokanson, John E and Lynch, David A and Humphries, Stephen M and Ross, James C and Cho, Michael H and Hersh, Craig P and Crapo, James D and Strand, Matthew and Silverman, Edwin K},
title = {Heterogeneity and Progression of Chronic Obstructive Pulmonary Disease: Emphysema-Predominant and Non–Emphysema-Predominant Disease},
journal = {American Journal of Epidemiology},
year = {2023},
volume = {192},
number = {10},
pages = {1647--1658},
doi = {10.1093/aje/kwad114}
}
EUVIMED